Developing first-in-class
therapies for gynaecologic
conditions with significant
unmet needs

Uterine Fibroids

Preserving the integrity
of womanhood

Endometriosis

Changing the rules of
treatment, drug performance
and innovations

Infertility

Pioneering first-in-class
medical treatments
in reproductive medicine

Post-Surgical Adhesions

PregLem SA is a Swiss-based speciality biopharmaceutical company dedicated to the development and commercialization of innovative drugs for women’s reproductive medicine. PregLem is a member of the Richter Group.

PregLem’s activities focus on developing therapies for gynaecologic conditions with significant unmet needs and that have a severe impact on the patient’s quality of life:

 

Research & Development

Esmya®
(Ulipristal Acetate/PGL4001)

Completed Ph III
EMA approval as a pre-operative treatment of moderate to severe symptoms of uterine fibroids received in February 2012

PGL2001
(Steroid Sulfatase Inhibitor, STS-I)

Mild or Moderate Endometriosis: Phase IIa

PGL5001
(c-Jun-N-Terminal Kinase Inhibitor (JNK-I), Bentamapimod)
Inflammatory Endometriosis: Phase IIa / Proof of Concept (POC)
Adhesions: Phase IIa/Proof of Concept (POC)

PGL1001
(Somatostatin Antagonist, SST-ATG)

Ovarian Reserve Modulation: Pre-clinical development

Publications

2 Feb 2012
Uterine Fibroids and Evidence-Based Medicine — Not an Oxymoron
Elizabeth A. Stewart, M.D.
2 Feb 2012
Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids
Donnez et al.
2 Feb 2012
Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery
Donnez, et al.
23 Sep 2011
Selective progesterone receptor modulators in reproductive medicine
Bouchard P, Chabbert-Buffet N, Fauser BC.
25 Feb 2011
Inhibition of steroid sulfatase decreases endometriosis in an in vivo murine model.
S. Colette, S. Defrère, J.C. Lousse, A. Van Langendonckt, J.P. Gotteland, E. Loumaye, and J. Donnez